HUP0000527A3 - Process to prepare tolterodine and the intermediate - Google Patents

Process to prepare tolterodine and the intermediate

Info

Publication number
HUP0000527A3
HUP0000527A3 HU0000527A HUP0000527A HUP0000527A3 HU P0000527 A3 HUP0000527 A3 HU P0000527A3 HU 0000527 A HU0000527 A HU 0000527A HU P0000527 A HUP0000527 A HU P0000527A HU P0000527 A3 HUP0000527 A3 HU P0000527A3
Authority
HU
Hungary
Prior art keywords
tolterodine
prepare
prepare tolterodine
Prior art date
Application number
HU0000527A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of HUP0000527A2 publication Critical patent/HUP0000527A2/hu
Publication of HUP0000527A3 publication Critical patent/HUP0000527A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
HU0000527A 1996-12-31 1997-12-18 Process to prepare tolterodine and the intermediate HUP0000527A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3396196P 1996-12-31 1996-12-31
PCT/US1997/022521 WO1998029402A1 (en) 1996-12-31 1997-12-18 Process to prepare tolterodine

Publications (2)

Publication Number Publication Date
HUP0000527A2 HUP0000527A2 (hu) 2001-11-28
HUP0000527A3 true HUP0000527A3 (en) 2001-12-28

Family

ID=21873473

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000527A HUP0000527A3 (en) 1996-12-31 1997-12-18 Process to prepare tolterodine and the intermediate

Country Status (23)

Country Link
US (1) US5922914A (hu)
EP (1) EP0960109B1 (hu)
JP (1) JP4199310B2 (hu)
KR (2) KR20000057548A (hu)
CN (1) CN1151141C (hu)
AT (1) ATE226949T1 (hu)
AU (1) AU717985B2 (hu)
CA (1) CA2273789C (hu)
CZ (1) CZ295477B6 (hu)
DE (1) DE69716767T2 (hu)
DK (1) DK0960109T3 (hu)
ES (1) ES2186018T3 (hu)
FI (1) FI991477A0 (hu)
HK (1) HK1023566A1 (hu)
HU (1) HUP0000527A3 (hu)
NO (1) NO317158B1 (hu)
NZ (1) NZ336533A (hu)
PL (1) PL191603B1 (hu)
PT (1) PT960109E (hu)
RU (1) RU2176246C2 (hu)
SI (1) SI0960109T1 (hu)
SK (1) SK283591B6 (hu)
WO (1) WO1998029402A1 (hu)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU728395B2 (en) * 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE60022916T2 (de) 1999-07-01 2006-07-06 Pharmacia & Upjohn Co. Llc, Kalamazoo Reboxetin zur Behandlung von peripheren Neuropathien
US6566537B2 (en) 1999-12-30 2003-05-20 Pharmacia Ab Process and intermediates
SE9904850D0 (sv) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
DE10028443C1 (de) * 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen
DE10033016A1 (de) * 2000-07-07 2002-01-24 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen
PE20020547A1 (es) 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma
US20030027856A1 (en) * 2001-06-29 2003-02-06 Aberg A.K. Gunnar Tolterodine metabolites
IN191835B (hu) 2001-08-03 2004-01-10 Ranbaxy Lab Ltd
ATE418534T1 (de) 2001-10-26 2009-01-15 Pharmacia & Upjohn Co Llc Quaternäre ammoniumverbindungen und deren verwendung als antimuscarinische wirkstoffe
US7005449B2 (en) 2002-04-23 2006-02-28 Pharmacia & Upjohn Company Tolterodine salts
CN1668585A (zh) 2002-07-08 2005-09-14 兰贝克赛实验室有限公司 用作蝇蕈碱受体拮抗剂的3,6－二取代氮杂双环[3.1.0]己烷衍生物
DE60226906D1 (de) 2002-07-31 2008-07-10 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo ä3.1.0ühexanderivate, die sich als muscarinrezeptorantagonisten eignen
WO2004014363A1 (en) 2002-08-09 2004-02-19 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonist
EP1534675B1 (en) 2002-08-23 2009-02-25 Ranbaxy Laboratories, Ltd. Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo¬3.1.0 hexane derivatives as muscarinic receptor antagonists
MXPA05002302A (es) * 2002-08-28 2005-06-08 Pharmacia Corp Composicion liquida oral de tolterodina.
DE60227576D1 (de) 2002-12-10 2008-08-21 Ranbaxy Lab Ltd 3,6-DISUBSTITUIERTE AZABICYCLO i3.1.0 -HEXANDERIVATIVE ALS ANTAGONISTEN DES MUSCARINREZEPTORS
ATE386738T1 (de) 2002-12-23 2008-03-15 Ranbaxy Lab Ltd Flavaxat-derivate als muscarin-rezeptor antagonisten
AU2002347552A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CA2517824A1 (en) * 2003-03-06 2004-09-16 Neela Praveen Kumar 3,3-diarylpropylamine derivatives and processes for isolation thereof
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2004089281A2 (en) * 2003-04-08 2004-10-21 Hetero Drugs Limited Novel polymorphs of tolterodine tartrate
AU2003214520A1 (en) 2003-04-09 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003223010A1 (en) 2003-04-10 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
ATE362364T1 (de) 2003-04-10 2007-06-15 Ranbaxy Lab Ltd Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
BRPI0409302A (pt) 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
ITMI20031354A1 (it) * 2003-07-02 2005-01-03 Istituto Di Chimica Biomolecolare D El Cnr Sezione Sintesis enantioselettiva di composti enantiomericamente arricchiti.
ES2235648B1 (es) * 2003-12-22 2006-11-01 Ragactives, S.L. Procedimiento para la obtencion de tolterodina.
EP1701932B1 (en) * 2003-12-24 2012-07-18 Cipla Ltd. Tolterodine, compositions and uses thereof, and preparation of the same
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
ITMI20041920A1 (it) * 2004-10-11 2005-01-11 Chemi Spa Processo per la preparazione di n, n-diisopropil-3-2-idrossi-5-metilfenil-3-fenil-propabammina
US7355077B2 (en) * 2004-10-28 2008-04-08 Dr. Reddy's Laboratories Limited Process for preparing tolterodine
JP4513535B2 (ja) * 2004-12-03 2010-07-28 住友化学株式会社 トルテロジンの製造方法
EP1843999A1 (en) * 2005-01-10 2007-10-17 Teva Pharmaceutical Industries Ltd Process for preparing tolterodine tartrate
US7528267B2 (en) 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes
ES2268987B1 (es) * 2005-08-05 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de 3,3-difenilpropilaminas.
WO2007039918A1 (en) * 2005-10-06 2007-04-12 Natco Pharma Limited Novel process for the preparation of tolterodine
EP1948164A1 (en) 2005-10-19 2008-07-30 Ranbaxy Laboratories, Ltd. Pharmaceutical compositions of muscarinic receptor antagonists
KR100686351B1 (ko) * 2006-01-12 2007-02-22 주식회사 카이로제닉스 톨테로딘 라세미체의 제조방법
ITMI20060110A1 (it) * 2006-01-24 2007-07-25 Dipharma Spa Procedimento per la purificazione di tolterodina
DK2029567T3 (da) 2006-05-24 2010-11-29 Pfizer Ltd Fremgangsmåde til frembringelse af benzopyran-2-ol-derivater
US7268257B1 (en) 2006-05-31 2007-09-11 Sumitomo Chemical Company, Limited Process for producing tolterodine
CZ302585B6 (cs) * 2007-02-26 2011-07-20 Zentiva, A. S. Krystalická sul 2-[(1R)-3-[bis(1-methylethyl)amino]-1-fenylpropyl]-4-methylfenolu s kyselinou (2R,3R)-2,3-dihydroxybutandiovou
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
KR101188333B1 (ko) * 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
ITMI20082055A1 (it) * 2008-11-19 2009-02-18 Dipharma Francis Srl Procedimento per la preparazione di (r)-tolterodina base libera
WO2010092500A2 (en) 2009-02-12 2010-08-19 Alembic Limited A process for the preparation of tolterodine tartrate
EP2398765A1 (en) * 2009-02-17 2011-12-28 Pharmathen S.A. Improved process for the preparation of (r)-2-(3-diisopropylamino)-1-phenylpropyl)-4methylphenol and salts thereof
ES2604705T3 (es) 2010-03-31 2017-03-08 Ono Pharmaceutical Co., Ltd. Agente preventivo y/o remedio para el síndrome mano-pie
WO2012098044A1 (en) 2011-01-17 2012-07-26 Cambrex Profarmaco Milano S.R.L. Process for the preparation of n,n-diisopropyl-3-(2-hydroxy-5-methylphenyl)- 3-phenyl propylamine and its salts starting from a novel intermediate
EP2476665A1 (en) 2011-01-17 2012-07-18 Cambrex Profarmaco Milano S.r.l. Process for the preparation of N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)- 3-phenyl propylamine and its salts starting from a novel intermediate
CN102516098B (zh) * 2011-12-09 2014-06-18 北京联本医药化学技术有限公司 酒石酸托特罗定制备方法
CN103044274B (zh) * 2012-11-29 2014-10-22 珠海保税区丽珠合成制药有限公司 一种无溶剂合成酒石酸托特罗定的方法
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
CN110229072B (zh) * 2019-06-25 2022-04-08 中国药科大学 一种托特罗定及其对映体的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE8800207D0 (sv) * 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5482967A (en) * 1992-09-04 1996-01-09 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use

Also Published As

Publication number Publication date
PL191603B1 (pl) 2006-06-30
AU717985B2 (en) 2000-04-06
CA2273789A1 (en) 1998-07-09
PT960109E (pt) 2003-03-31
NZ336533A (en) 2000-05-26
EP0960109A1 (en) 1999-12-01
CN1238768A (zh) 1999-12-15
EP0960109B1 (en) 2002-10-30
SI0960109T1 (en) 2003-04-30
ES2186018T3 (es) 2003-05-01
AU5956998A (en) 1998-07-31
NO993247D0 (no) 1999-06-29
ATE226949T1 (de) 2002-11-15
DE69716767D1 (de) 2002-12-05
HK1023566A1 (en) 2000-09-15
FI991477A (fi) 1999-06-29
SK81599A3 (en) 1999-12-10
CN1151141C (zh) 2004-05-26
WO1998029402A1 (en) 1998-07-09
CZ227299A3 (cs) 1999-11-17
DK0960109T3 (da) 2002-11-25
KR20000057548A (ko) 2000-09-25
JP2001507691A (ja) 2001-06-12
FI991477A0 (fi) 1999-06-29
PL334375A1 (en) 2000-02-28
KR100463614B1 (ko) 2004-12-29
HUP0000527A2 (hu) 2001-11-28
CA2273789C (en) 2006-06-06
SK283591B6 (sk) 2003-10-07
CZ295477B6 (cs) 2005-08-17
US5922914A (en) 1999-07-13
RU2176246C2 (ru) 2001-11-27
NO317158B1 (no) 2004-08-30
NO993247L (no) 1999-08-09
KR20000069771A (ko) 2000-11-25
JP4199310B2 (ja) 2008-12-17
DE69716767T2 (de) 2003-06-12

Similar Documents

Publication Publication Date Title
HUP0000527A3 (en) Process to prepare tolterodine and the intermediate
EP0708482A3 (en) BiCDMOS manufacturing technology and its structures
AP9901444A0 (en) Erythrommycins and process for their preparation
GB2310670B (en) Firelogs and firelighters
GB9401969D0 (en) Process
EP0890599A4 (en) POLYORGANOSILOXANES AND METHOD FOR THE PRODUCTION THEREOF
GB9401780D0 (en) Modified plants
GB9402604D0 (en) Microbiologial process
GB9403133D0 (en) Process
GB9405592D0 (en) Process
GB9402607D0 (en) Process
GB2290934B (en) Plant supports
KR0108940Y1 (en) Sunshades
PL319673A1 (en) Biphenoles preparation process
GB9604314D0 (en) Plant phylogenisation
CA74621S (en) Ornament
AU121653S (en) Ornament
AU122775S (en) Ornament
AU122981S (en) Ornament
AU122980S (en) Ornament
GB9403188D0 (en) Improvements in canopies
PL57908Y1 (en) Structural shape
PL57871Y1 (en) Structural shape
GB9417769D0 (en) Plant
PL306261A1 (en) Concentrator

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished